Ticker: CRSP | Published: 2026-09-21
CRISPR cholesterol data lifts stock
CRSP is rallying moderately as investors react to reported gene-editing trial data showing a single infusion of its cholesterol therapy cut LDL sharply, with bullish coverage reinforcing the move.
Sources: https://english.pravda.ru/news/health/crispr-ctx310-cholesterol-trial/, https://www.fool.com/investing/2026/09/20/reasons-crispr-therapeutics-stock-is-st